论文部分内容阅读
目的:观察易善力治疗酒精性肝病的疗效并探讨其机制.方法:64例酒精性肝病患者随机分为治疗组35例和对照组29例,治疗组给予易善力注射液500mg(2支)加于10%葡萄糖溶液250ml.静脉点滴,每日一次;对照组应用谷胱甘肽600mg加于10%葡萄糖溶液250ml.静脉点滴,每日一次.两组均给予戒酒、支持、多种维生素等辅助治疗,疗程8wk.结果:治疗组易善力对酒精性肝病患者的症状体征明显改善,B超测定肝右径明显缩小,ALT、AST、GGT等明显下降,显效率62.96%,有效率25.93%,总有效率为88.89%;对照组谷胱甘肽的显效率55.56%,有效率29.63%,总有效率为84.6%.在血清肝纤维化HA和PⅢP标志改善方面,治疗组优于对照组.结论:易善力是一种治疗酒精性肝病的有效药物,可能对抗酒精性肝纤维化有一定作用,无明显副作用.
Objective: To observe the curative effect of Yishenli on alcoholic liver disease and explore its mechanism.Methods: 64 cases of alcoholic liver disease were randomly divided into treatment group (35 cases) and control group (29 cases). The treatment group was given Yishenli injection 500mg ) Was added to 10% glucose solution 250ml intravenously once daily; control group glutathione 600mg plus 10% glucose solution 250ml intravenous drip once daily.The two groups were given alcohol, support, a variety of Vitamins and other adjuvant therapy, treatment 8wk.Results: The treatment group Yi Shanli symptoms and signs of patients with alcoholic liver disease significantly improved, B-measured right hepatic diameter was significantly reduced, ALT, AST, GGT decreased significantly, the effective rate was 62.96%, with The effective rate was 25.93%, the total effective rate was 88.89%; the effective rate of glutathione in the control group was 55.56%, the effective rate was 29.63%, the total effective rate was 84.6% .As for the improvement of serum HA and PⅢP in serum fibrosis, In the control group.Conclusion: Yishenli is an effective drug for the treatment of alcoholic liver disease, which may have some effect on alcoholic liver fibrosis with no obvious side effects.